The Product Safety & Liability Reporter™ provides updates on significant developments and issues in product safety and liability litigation and regulation, plus analysis from top litigators. Get...
Aug. 29 — Non-Illinois families may pursue in Illinois their allegations that GlaxoSmithKline LLC's drug Paxil caused their children's birth defects ( M.M. v. GlaxoSmithKline LLC, 2016 BL 280136, Ill. App. Ct., No. 2014 L 006985, 8/26/16 ).
The families allege the birth defects were caused by the mothers' use of the antidepressant Paxil during pregnancy.
Illinois courts have specific jurisdiction over GSK because of its activities in the state, the Illinois Appeals Court said Aug. 26.
The plaintiffs are eight children and their mothers. Two mother-child pairs are Illinois residents.
“GSK is disappointed by the court's decision and is considering its options,” a GSK spokesperson told Bloomberg BNA.
GSK conceded it had purposefully directed its activities at the state, but denied that the plaintiffs' claims arose from those actions. The company said there was no meaningful link between the plaintiffs' claims and the small fraction of Paxil trials it conducted in Illinois.
But jurisdiction would exist even absent the company's concession, the appeals court said. The company purposefully availed itself of the state's benefits by contracting with 17 Illinois physicians to run between 18 and 21 Paxil clinical trials in Illinois as part of a study running nearly two decades.
The plaintiffs' claims arose from the drugmakers' conduct related to the clinical trials, the court said.
Plaintiffs alleged GSK failed to conduct appropriate research on Paxil and birth defects, failed to sufficiently investigate the drug for safety, manipulated data to conceal a birth defect risk and falsely affirmed that Paxil was adequately tested, the court said.
This data was aggregated with the data from other locations, and GSK drew safety conclusions from the single set of data, plaintiffs argued.
This resulted in inadequate warning labels, plaintiffs said.
TorHoerman Law LLC represented the plaintiffs.
Dentons US LLP represented GSK.
To contact the reporter on this story: Julie A. Steinberg in Washington at firstname.lastname@example.org
The opinion is available at http://www.bloomberglaw.com/public/document/MM_v_GlaxoSmithKline_LLC_2016_IL_App_1st_151909_Court_Opinion.
Copyright © 2016 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)